奥精医疗科技股份有限公司2025 年半年度报告 公司代码：688613 公司简称：奥精医疗 奥精医疗科技股份有限公司 2025 年半年度报告 1 / 175 奥精医疗科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 报告期内，不存在对公司产生实质性重大不利影响的风险因素。公司已在本报告中详细描述了公 司可能面对的风险，具体内容敬请查阅本报告"第三节管理层讨论与分析"。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人崔孟龙、主管会计工作负责人王玲及会计机构负责人（会计主管人员）苗晓英 声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质承诺，敬请投资者 注 ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-048 奥精医疗科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本公告披露日，奥精医疗科技股份有限公司（以下简称 "公司" 或"奥精医疗"）股东 BioVeda China RMB Investment Limited（以下简 称 "BioVeda"）持有奥精医疗 7,239,358 股股份，占奥精医疗总股份的 5.28%。上述股份为 BioVeda 于公司首次公开发行并上市前取得的股份，且 于 2022 年 5 月 23 日起上市流通。 | 一、减持主体的基本情况 | | --- | | 股东名称 | BioVeda | | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 □是 √否 | 1 预披露期间，若公司股票发生停牌情形的，实际开始减持的时间根据停牌时间相应顺延 2 直接持股 5%以上股东 √是 □否 董事、监事和高级管理人员 □是 √ ...

格隆汇8月29日｜奥精医疗公告，公司于近日收到BioVeda出具的《关于股份减持计划的告知函》，因自 身资金安排，BioVeda将根据市场情况通过集中竞价、大宗交易进行减持。BioVeda计划通过集中竞价、 大宗交易方式减持奥精医疗股份不超过1355515股，占奥精医疗总股份的1%。减持期间为2025年9月22 日~2025年12月22日。 ...

每经AI快讯，8月29日，奥精医疗（688613）(688613.SH)公告称，股东BioVeda计划通过集中竞价、大 宗交易方式减持公司股份不超过1,355,515股，占公司总股份的1%。减持期间为2025年9月22日至2025年 12月22日。 ...

Core Viewpoint - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the second batch of selected units for the innovative task of biomedical materials, with Aojing Medical (688613.SH) leading the "degradable semi-hydrated calcium sulfate" project [1][2]. Industry Overview - Biomedical materials are referred to as the "chip of medical devices" and are crucial for the localization of high-end medical equipment. However, China faces significant challenges in the fields of degradable bone repair materials and magnesium alloys, with over 60% of the high-end bone repair materials market being occupied by imported products [1][2]. - The current market for bone repair materials is dominated by foreign companies that monopolize core technologies, leading to high prices and clinical standard dominance, which exacerbates accessibility issues for domestic patients [1]. Company Positioning - Aojing Medical is recognized as a leading enterprise in the field of mineralized collagen bone repair materials, with a strong commitment to long-term R&D investment and a multidisciplinary research team [2][3]. - The company has accumulated substantial technical reserves in key areas such as high-end regenerative medical materials and advanced manufacturing processes, and has undertaken numerous national and provincial major R&D projects [2]. Strategic Importance - The successful selection in the "revealing the list" initiative signifies national endorsement of Aojing Medical's technological route and R&D capabilities, positioning the company as a leader in the domestic high-end bone repair materials sector [3][4]. - Aojing Medical aims to collaborate with universities and hospitals to tackle key technical challenges, conduct multi-center clinical trials, and establish clinical standards, thereby shortening product launch cycles and enhancing the overall value of China's biomedical materials industry [3]. Market Potential - The market for bone repair materials in China is projected to exceed 35 billion yuan by 2030, with a domestic production rate expected to surpass 70%. The share of degradable materials is anticipated to increase from 15% to 40% [3].

Core Viewpoint - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the second batch of selected units for the innovative task of biomedical materials, with Aojing Medical (688613.SH) leading the "degradable semi-hydrated calcium sulfate" project team, highlighting the company's role in addressing the domestic challenges in high-end bone repair materials [1][2]. Industry Overview - Biomedical materials are referred to as the "chips of medical devices" and are crucial for the localization of high-end medical equipment. Currently, over 60% of the high-end bone repair materials market in China is dominated by imported products, leading to high costs and clinical standard monopolization by foreign companies [1][2]. - The degradable semi-hydrated calcium sulfate is a revolutionary material in bone defect repair, offering advantages such as good biocompatibility, self-curing properties, and adaptability to complex bone defects. However, the core technical challenge lies in maintaining a dynamic balance between degradation and bone regeneration [1][3]. Company Insights - Aojing Medical is recognized as a leading enterprise in the field of mineralized collagen bone repair materials, with a strong commitment to long-term R&D investment and a multidisciplinary research team. The company has accumulated significant technical reserves in key areas such as high-end regenerative medical materials and advanced manufacturing processes [2][3]. - The successful selection in the "revealing the list" initiative signifies Aojing Medical's leadership in the domestic high-end bone repair materials sector. The company aims to collaborate with universities and hospitals to tackle key technical challenges and streamline clinical standard development, thereby enhancing its integrated industry chain from material research to clinical application [3][4]. Market Potential - Under the guidance of the "Healthy China 2030" strategy, the biomedical materials industry is entering a golden development period. According to Frost & Sullivan, the market size for bone repair materials in China is expected to exceed 35 billion yuan by 2030, with the localization rate likely surpassing 70%. The proportion of degradable materials is projected to increase from the current 15% to 40% [3].

Core Viewpoint - The article discusses the announcement of the second batch of selected units for the "Innovation Task of Biomedical Materials" by the Ministry of Industry and Information Technology, highlighting various innovative materials and their respective companies involved in their development [2][3]. Group 1: Polymer Materials - Key materials include Polyethylene Terephthalate, Phosphorylcholine-based Polymers, High Purity Acrylic Monomers, and High Oxygen Permeability Silicones [3][4]. - Companies involved in these materials include China Petrochemical Corporation, Weigao Group, and Jiangsu New Vision Advanced Functional Fiber Innovation Center [4][5]. - Other notable materials are Dendritic Light-sensitive Smart Materials and Anti-thrombus New Materials, with companies like Jiangsu Baisei Biotechnology and BoHui (Zhejiang) Biotechnology [3][6]. Group 2: Metal Materials - Key materials in this category include Ultra-fine Crystal Titanium Rod Wire, Porous Tantalum, Zirconium Niobium Alloys, and High-end Stainless Steel Wire [7][8]. - Companies such as Baoji Xinnuo Special Materials and Shenzhen Shigesaisi Medical Technology are involved in the production of these materials [9]. Group 3: Inorganic Non-metallic Materials - Important materials include Degradable Semi-hydrated Calcium Sulfate, Silicon Nitride Ceramics, and 3D Printing Zirconia Ceramic Inks [10][11]. - Companies like Zhongding Kairui Technology and Beijing Bansai Technology are engaged in the development of these materials [11].

Group 1 - The core viewpoint of the news is that Aojing Medical's stock performance and financing activities indicate a low level of investor confidence, with a net financing buy of -58.05 million yuan on August 26 [1] - As of August 26, Aojing Medical's total financing and securities balance is 128 million yuan, which is 4.52% of its market capitalization, indicating a low financing level compared to the past year [1] - The company has not engaged in any short selling activities on August 26, with a short selling balance of 0, suggesting a lack of bearish sentiment among investors [1] Group 2 - As of March 31, Aojing Medical had 7,905 shareholders, a decrease of 2.85% from the previous period, while the average number of circulating shares per shareholder increased by 2.93% to 17,147 shares [2] - For the first quarter of 2025, Aojing Medical reported a revenue of 42.46 million yuan, a year-on-year decrease of 10.35%, and a net profit attributable to shareholders of 1.04 million yuan, down 84.99% year-on-year [2] - The company has distributed a total of 58.67 million yuan in dividends since its A-share listing, with 22.40 million yuan distributed over the past three years [3]

天眼查商业履历信息显示，奥精医疗科技股份有限公司，成立于2004年，位于北京市，是一家以从事医 药制造业为主的企业。企业注册资本13555.1584万人民币，实缴资本13555.1584万人民币。公司法定代 表人为胡刚。 通过天眼查大数据分析，奥精医疗科技股份有限公司共对外投资了8家企业，参与招投标项目131次，知 识产权方面有商标信息48条，专利信息134条，此外企业还拥有行政许可21个。 来源：金融界 金融界消息 截至2025年8月25日收盘，奥精医疗（688613）报收于20.68元，下跌1.15%，换手率 3.59%，成交量4.92万手，成交金额1.03亿元。 资金流向方面，今日主力资金净流出1133.35万元，占比成交额11.05%。其中，超大单净流出610.54万 元、占成交额5.95%，大单净流出522.81万元、占成交额5.1%，中单净流出流入523.69万元、占成交额 5.11%，小单净流入609.66万元、占成交额5.94%。 奥精医疗最新一期业绩显示，截至2025一季报，公司营业总收入4245.97万元、同比减少10.35%，归属 净利润104.15万元，同比减少84.99%，扣非净利润 ...

Group 1 - The core point of the news is that AoJing Medical has seen a financing buy-in amount of 0.12 billion yuan on August 22, ranking 1432nd in the two markets, with a net sell of 798,600 yuan on the same day [1] - Over the last three trading days from August 20 to August 22, AoJing Medical received financing buy-ins of 0.11 billion yuan, 0.10 billion yuan, and 0.12 billion yuan respectively [1] Group 2 - In terms of securities lending, there were no shares sold or net sold on the same day [2]